These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
518 related articles for article (PubMed ID: 16728631)
21. Radiation combined with antiangiogenic and antivascular agents. O'Reilly MS Semin Radiat Oncol; 2006 Jan; 16(1):45-50. PubMed ID: 16378906 [TBL] [Abstract][Full Text] [Related]
22. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Head M; Jameson MB Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Schultze A; Fiedler W Expert Opin Investig Drugs; 2010 Jun; 19(6):777-88. PubMed ID: 20465362 [TBL] [Abstract][Full Text] [Related]
24. Targeting angiogenesis with integrative cancer therapies. Yance DR; Sagar SM Integr Cancer Ther; 2006 Mar; 5(1):9-29. PubMed ID: 16484711 [TBL] [Abstract][Full Text] [Related]
25. Angiogenesis: from plants to blood vessels. Fan TP; Yeh JC; Leung KW; Yue PY; Wong RN Trends Pharmacol Sci; 2006 Jun; 27(6):297-309. PubMed ID: 16697473 [TBL] [Abstract][Full Text] [Related]
26. Microtubule-targeting agents in angiogenesis: where do we stand? Pasquier E; Honoré S; Braguer D Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139 [TBL] [Abstract][Full Text] [Related]
33. Angiogenesis and cancer: recent advances. Cáceres W; González S P R Health Sci J; 2003 Jun; 22(2):149-51. PubMed ID: 12866139 [TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Cao Y Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094 [TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug? Cao Y Int J Dev Biol; 2011; 55(4-5):557-62. PubMed ID: 21858776 [TBL] [Abstract][Full Text] [Related]
37. [Metronomic chemotherapy in 2011: update and perspectives]. Benbrahim Z; Massard C; El Mesbahi O Bull Cancer; 2011 Dec; 98(12):1447-54. PubMed ID: 22146261 [TBL] [Abstract][Full Text] [Related]
38. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. Folkman J Exp Cell Res; 2006 Mar; 312(5):594-607. PubMed ID: 16376330 [TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic therapy for cancer: an update. Shojaei F; Ferrara N Cancer J; 2007; 13(6):345-8. PubMed ID: 18032969 [TBL] [Abstract][Full Text] [Related]
40. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Mazeron R; Anderson B; Supiot S; Paris F; Deutsch E Cancer Treat Rev; 2011 Oct; 37(6):476-86. PubMed ID: 21546163 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]